-
Molecular Profiling for Metastatic Colorectal Cancer and the Future of the Disease
“A better understanding of the heterogeneity of mCRC, including primary tumor location, microsatellite instability (MSI) status, and other clinically actionable tumor mutations, is reshaping the therapeutic landscape,” Dr. Benjamin Weinberg and Dr. Samantha Armstrong explain.
Category: News
-
Today’s Molecular Profiling Efforts Will Define the New Decade of GI Cancer Management
Over the past decade in gastrointestinal cancer treatment, the acknowledgement that cancer is heterogeneous and likely polyclonal has prompted a shift from gene testing for some patients, to many patients.
Category: News
-
Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types
Learn from the experts including Dr. John Marshall, Dr. Jamie Chaft, MD and Scot Niglio, MD, about current and emerging immuno-oncology biomarkers to guide selection of optimal cancer treatment across tumor types. Participate in the interactive CCO Webinar or watch the on-demand Webcast and download the slides. Listen to a podcast for answers to FAQs asked during the live Webinar.
Category: News
-
No-Visitor Policies Are Bad Medicine
According to Dr. John Marshall, “Cancer care is not elective; it has to keep going. One of the worst policies for our patients right now is this no-visitor policy. You are coming for a treatment, a clinic visit, or, worse yet, admitted to the hospital for end-of-life care or for some complex medical procedure related to your cancer, and yet you can’t have a caregiver, an advocate, sitting next to you in your room.”
Category: News
-
Glimmers of Hope- New Strategies for Overcoming Treatment Resistance in Patients with BRAF-V600E-Mutated Metastatic Colorectal Cancer
BRAF V600E-mutated metastatic colorectal cancer is notoriously difficult to treat due to an aggressive tumor biology and resistance to chemotherapy.
Category: News
-
Meet PanCan Research Grantee: Jill Smith, MD
Jill Smith, MD, has a message for patients with pancreatic cancer: “Never lose hope, be strong and be encouraged.” Smith, a clinician-scientist and professor of medicine at Georgetown University and a member of the Georgetown Lombardi Comprehensive Cancer Center, tries to model those tenets herself.
Category: News
-
Justice Ruth Bader Ginsburg says she is being treated for recurrence of cancer
“The treatment she is getting is typical for pancreatic cancer. That would fit,” said John L. Marshall, director of the Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center. “But her cancer history is very unusual, from a good perspective. She’s always done much better than one would have anticipated.”
Category: News
-
Dr. Jill Smith Receives Pancreatic Cancer Action Network Innovative Research Competitive Grant
In this Pancreatic Cancer Action Network Translational Research Grant project, Dr. Smith’s team will study the effects of a drug, proglumide, and its actions to render pancreatic cancer more responsive to therapy.
Category: News
-
Practice-Changing GI Cancer Highlights From Virtual ASCO 2020
Dr. John Marshall shares his personal highlights of GI cancers research from this year’s ASCO conference. There were a lot of important, practice-changing data and he touches on some big-picture themes that are really starting to hit home in GI cancer.
Category: News
-
Georgetown Lombardi Clinical Trial Helps Advance Use of Immunotherapy in Liver Cancer
In August of 2016, Dan Hilton arrived at MedStar Georgetown University Hospital to be evaluated for a liver transplant. He had been diagnosed with cirrhosis, the result of a hepatitis C infection contracted many years earlier. After multiple tests, he received unexpected news; the doctors found tumors on his liver.
Category: News